2nd Quarter - Report
OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Medical Innovation
| Lobbyist | Covered position, as disclosed |
|---|---|
| ORKIDEH MALKOC | — |
Health Issues HCR
ADPKD (Autosomal dominant polycystic kidney disease); H.R.6082 OVERDOSE PREVENTION AND PATIENT SAFETY ACT - 42 CFR Part 2 - Federal confidentiality law and regulations; Health Care issuses as it relates to TBI (Traumatic Brain Injuries) Clinical Trials
| Lobbyist | Covered position, as disclosed |
|---|---|
| ORKIDEH MALKOC | — |
| MOLLY RYAN | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| AVANIR PHARMACEUTICALS | Aliso Viejo, CA, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.